By Cormac Sheridan, Staff Writer – Published by BioWorld™ – The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a target in autoimmune disease that has evaded the best efforts…

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late summer 2023 – San Diego, CA, USA, and Munich, Germany…